Carbamazepine, first synthesized in 1953, was initially marketed in Europe as an anticonvulsant. In 1971 Dalby reported the drug's psychotropic effects, most notably mood stabilization, in patients with temporal lobe epilepsy (TLE) (1). Other psychiatric applications such as the treatment of affectively and behaviorally labile patients are being explored. These studies are yielding data relevant to the treatment and understanding of the neurobiology of mental illness. For this reason, familiarity with carbamazepine is becoming increasingly important to psychiatrists.
Kim, MD, Edward
"Uses of Carbamazepine for Psychiatric Disorders: A Review,"
Jefferson Journal of Psychiatry:
2, Article 10.
Available at: http://jdc.jefferson.edu/jeffjpsychiatry/vol6/iss2/10